{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:09:47Z","timestamp":1762376987551,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.breast.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T17:28:29Z","timestamp":1629739709000},"page":"35-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Underutilisation of breast cancer prevention medication in Australia"],"prefix":"10.1016","volume":"60","author":[{"given":"Courtney","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-9749","authenticated-orcid":false,"given":"James A.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-7268","authenticated-orcid":false,"given":"Roger L.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-4068","authenticated-orcid":false,"given":"Kelly-Anne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.breast.2021.08.013_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat Rev Canc"},{"issue":"1","key":"10.1016\/j.breast.2021.08.013_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2021.08.013_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet (London, England)"},{"year":"2010","series-title":"Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals","author":"Cancer Australia","key":"10.1016\/j.breast.2021.08.013_bib4"},{"issue":"2","key":"10.1016\/j.breast.2021.08.013_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10689-004-6129-x","article-title":"Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort","volume":"4","author":"Phillips","year":"2005","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.breast.2021.08.013_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","volume":"110","author":"Lee","year":"2014","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.breast.2021.08.013_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13053-017-0075-8","article-title":"Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review","volume":"15","author":"Meiser","year":"2017","journal-title":"Hered Cancer Clin Pract"},{"issue":"7","key":"10.1016\/j.breast.2021.08.013_bib8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br. J. Canc."},{"issue":"3","key":"10.1016\/j.breast.2021.08.013_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10549-018-4775-1","article-title":"Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews","volume":"170","author":"Hackett","year":"2018","journal-title":"Breast Canc Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2021.08.013_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.breast.2021.08.013_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/154099903322447738","article-title":"Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer","volume":"12","author":"Meiser","year":"2003","journal-title":"J\u00a0Womens Health (Larchmt)"},{"issue":"1","key":"10.1016\/j.breast.2021.08.013_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1940-6207.CAPR-20-0369","article-title":"Breast cancer chemoprevention: use and views of Australian women and their clinicians","volume":"14","author":"Macdonald","year":"2021","journal-title":"Canc Prev Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:49Z","timestamp":1760777029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"alternative-id":["S0960977621004434"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.08.013","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underutilisation of breast cancer prevention medication in Australia","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}